School of Medicine, Cardiff University, UK.
Great Ormond Street Hospital, London, UK.
Haemophilia. 2018 May;24(3):344-347. doi: 10.1111/hae.13495.
Emicizumab is a bispecific antibody that activates FX to FXa in the absence of FVIII. It has been shown to reduce bleeding episodes in people with haemophilia A complicated by a FVIII inhibitor. Despite the protection against bleeds, some breakthrough bleeds are inevitable and these may require additional haemostatic treatment. Emicizumab has been associated with severe adverse events when co-administered with activated prothrombin complex concentrate. To minimize the risk of adverse events, the UK Haemophilia Centre Doctors' Organisation issues the following updated interim guidance to its Inhibitor Guidelines for managing patients receiving Emicizumab based on the limit published information available in February 2018.
依库珠单抗是一种双特异性抗体，可在缺乏 FVIII 的情况下将 FX 激活为 FXa。它已被证明可减少伴有 FVIII 抑制剂的 A 型血友病患者的出血发作。尽管可以预防出血，但仍不可避免地会出现一些突破性出血，这些出血可能需要额外的止血治疗。当依库珠单抗与活化的凝血酶原复合物浓缩物联合使用时，会出现严重的不良反应。为了最大程度地降低不良反应的风险，英国血友病中心医生组织根据 2018 年 2 月发布的现有信息发布了最新的临时指南，对其抑制剂指南进行了更新，以管理接受依库珠单抗治疗的患者。
